Arcus Biosciences Inc. (RCUS)
Company Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.
The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease.
It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer.
The company was incorporated in 2015 and is headquartered in Hayward, California.

Country | United States |
IPO Date | Mar 15, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 627 |
CEO | Dr. Terry J. Rosen Ph.D. |
Contact Details
Address: 3928 Point Eden Way Hayward, California United States | |
Website | https://www.arcusbio.com |
Stock Details
Ticker Symbol | RCUS |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001724521 |
CUSIP Number | 03969F109 |
ISIN Number | US03969F1093 |
Employer ID | 47-3898435 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & Chief Executive Officer |
Jennifer A. Jarrett M.B.A. | Chief Operating Officer |
Robert C. Goeltz II | Principal Financial Officer & Chief Financial Officer |
Alexander Azoy CPA | Vice President of Finance & Principal Accounting Officer |
Carolyn C. Tang J.D. | General Counsel & Corporate Secretary |
Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President |
Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
Holli Kolkey | Vice President of Corporate Communications |
Pia Eaves | Vice President of Investor Relations & Strategy |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 05, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Feb 27, 2025 | 4 | Filing |
Feb 27, 2025 | 4 | Filing |
Feb 25, 2025 | S-8 | Filing |
Feb 25, 2025 | 10-K | Annual Report |
Feb 25, 2025 | 8-K | Current Report |
Feb 20, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Feb 20, 2025 | 4 | Filing |
Feb 19, 2025 | 8-K | Current Report |
Feb 18, 2025 | 424B5 | Filing |